The expansion marks the first therapy approved for patients with BCG-unresponsive non-muscle-invasive bladder cancer presenting with papillary-only disease.

(HealthDay News) — Among patients with cancer with a genetic variant that increases the risk for hereditary cancers, personalized support significantly increases the likelihood that their first-degree ...

(HealthDay News) — Less than 30 percent of women with estrogen receptor (ER)-positive early-stage breast cancer (ESBC) treated with lumpectomy remain adherent to endocrine therapy (ET) at five years, ...

Researchers conducted a systematic case review to characterize the clinical presentation and underlying malignancies associated with Bazex syndrome.

Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

Researchers evaluated the impact of olanzapine for CINV on CNS symptom burden in patients receiving AC-based chemotherapy.

In a new study, patients with intestinal inflammatory disease who received immune checkpoint inhibitor (ICI) therapy appeared to have increased risk of ...

A randomized phase 2 trial evaluated whether prophylactic goshajinkigan reduces the incidence of CIPN in patients receiving carboplatin plus paclitaxel.

Psychotherapy within one week of cancer diagnosis linked to 27 percent lower risk for cancer-specific mortality ...

Most women aware of modifiable behaviors to lower breast cancer risk, yet there is a gap between awareness and adoption of risk-cutting behaviors ...

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.

A systematic review and meta-analysis evaluated qualitative evidence on the experiences of MBC survivors to understand how they cope with associated challenges.